Home / Themes / MedTech Long '25 : US Drug Dev Outsourcing
MedTech Long '25 : US Drug Dev Outsourcing
Last updated
Theme thesis · 2/5 sections · Tickers 1 with notes · 7 pending
Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).
Bull / Bear DetailsThis basket benefits from a structural shift toward U.S.-based drug development and biopharma supply chain reshoring, catalyzed by Trump 2.0's trade war posture
Thesis
This basket benefits from a structural shift toward U.S.-based drug development and biopharma supply chain reshoring, catalyzed by Trump 2.0's trade war posture, RFK's anti-China HHS stance, and increasing executive/federal aversion to China-based CRO/CDMO services. Even without the BIOSECURE Act passing, the regulatory and reputational risk of relying on offshore services has spurred U.S.-focused demand, contract wins, and capital investment across the domestic life sciences value chain.
Bull case
BIOSECURE Act failed but reshoring persists: U.S. firms are still redirecting preclinical and manufacturing work away from China to domestic providers like TKNO, NOTV, and FTRE despite the act not passing
Funding inflects off the bottom: Biopharma venture funding and pipeline activity have rebounded in early 2025, driving volume growth for U.S.-centric CRO/CDMOs across diagnostics and early-stage services
AI and organoid initiatives expand TAM: FDA support for AI and lab-based alternatives to animal testing (e.g. CERT, TKNO) is enhancing demand for domestic platforms with data and infrastructure advantages
Bear case
BIOSECURE failure signals policy fade: Without legislation, enforcement risks may ease and large pharma may delay or reverse onshoring investments.
China stimulus and cost arbitrage lure contracts back: Lower-cost Chinese providers may regain market share if political pressure eases or clients seek margin relief.
Capital expenditure slows in downturn: A broader market or biotech correction could delay infrastructure investments and contract volume for U.S.-based vendors.
Key Metrics
| Metric | Cadence | What It Signals | Update Source |
|---|---|---|---|
| U.S.-only biopharma CRO/CDMO contract flow and RFPs | Quarterly | Measures whether sponsors are selecting domestic over offshore providers. | Google_Sheets |
| BIOSECURE-related policy changes or procurement bans | Event-driven | Identifies changes to contract eligibility or funding restrictions tied to China. | Google_Sheets |
| Domestic biopharma capex and facility investment | Quarterly/Annual | Tracks buildout of U.S. drug manufacturing and development capacity. | Google_Sheets |
Constituents
- NOTVT3— Inotiv, Inc.
- AVTRT3· no notes yet
- CDMOT3· no notes yet
- CERTT3· no notes yet
- CRLT3· no notes yet
- CYRXT3· no notes yet
- FTRET3· no notes yet
- TKNOT3· no notes yet